Bigfoot Biomedical Closes $55M Series C Financing, Plans FDA Filing For Diabetes System
Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.
You may also be interested in...
Bigfoot Biomedical Secures $57M In New Funding To Support Commercialization Of Diabetes Management System
As Bigfoot awaits FDA clearance for its Bigfoot Unity System, the diabetes treatment company’s business model calls for packing the System as part of a one-stop-shop monthly subscription model.
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.
Market Intel: Bigfoot Biomedical, Beta Bionics Getting Pumped To Introduce Next-Gen Artificial Pancreas
The insulin pump market, which is dominated by four major players, is facing rising competition from smaller, innovative companies. This second part of a two-part series focuses on five emerging companies: Beta Bionics, Bigfoot Biomedical, Diabeloop, EOFlow and Ypsomed.